OSE Immunotherapeutics presents promising results for Tedopi® in ovarian cancer

OSE Immunotherapeutics announced that results from the Phase 2 TEDOVA study of Tedopi® will be presented at the 2026 ASCO Annual Meeting in Chicago. This treatment, targeting relapsed ovarian cancer, is being evaluated as monotherapy or in combination with Keytruda®, an anti-PD1 immune checkpoint inhibitor. This study, sponsored by ARCAGY-GINECO, compares Tedopi® to standard care in 185 patients. The primary endpoint is progression-free survival after platinum-based chemotherapy. The results will be presented by Professor Alexandra Leary during the session on gynecological cancer.